製薬会社は、貧しいインド人のために薬を製造するわけではない、薬代をはらえる金持ちの欧州人などのために製造するのだ、(つまり金儲けのために！)
“No creamos medicamentos para indios, sino para los que pueden pagarlo”
El consejero delegado de Bayer pierde los nervios al discutir sobre patentes. En su disculpa afirma que su objetivo es tratar a todos
Emilio de Benito Madrid 24 ENE 2014 - 18:29 CET
"We did not create medicines for Indians, but for those who can afford"
Bayer CEO loses his temper when discussing patents. In his apology states that his goal is to treat all
Emilio de Benito Madrid 24 ENE 2014 - 18:29 CET
The discussion with the Indian authorities got out of their boxes to the CEO of Bayer. At stake was the patent for its anticancer Nexavar , a drug from generation to treat liver and kidney cancers . " We did not create this medicine for Indians, but for Westerners who can afford it," jumped Bayer CEO Marijn Dekkers . And several media have picked up later.
A former colleague of Dekkers , John LaMattina , gave occasion to apologize later. In an article in Forbes, the former executive of Pfizer criticizes his words. And that gave rise to Dekkers explain. Bayer refers to those statements.
"I regret that so a quick response in the context of a discussion has come to light in a way that I did not intend . Can not be more contrary to what I want and what we do at Bayer , "said Dekkers . As a company, " We want to improve the health and quality of life of the people, regardless of their origin or income." "In any case , I was particularly frustrated by the decision of the Indian government does not protect us Nexavar patent was granted patent authority in the country. I am convinced of our ability to innovate and an open discussion at the meeting, while expressing my basic frustration, I should have clarified this. "
more"The poor are worthless "Novartis claims that the Indian patent law is repealed by "unconstitutional "What is at stake in the battle of Glivec
"In any case , I reaffirm that there is no reason for a country to weaken the protection of intellectual property. No new drugs , both people in developing countries like those in other more affluent suffer , "he adds . He concluded by mentioning that while generic manufacturers have a " crucial role ", " do not invest in research and produce new cures or treatments or for developing markets and developed ."
The confrontation with India is just one of a large laboratory with a country that strictly enforces a patent law that leads them to reject the protection of some leading products ( most cases because they do not allow modifications to the original patent as research progresses in medicine , for example looking different salts ) . It was what led to the conflict with other anticancer Novartis ( Glivec ) . With this policy, the Indian government not only gets the patent lasts less ( which requires laboratories to lower their prices to compete ), but protects its thriving generic industry.
Doctors Without Borders, a militant organization that uses many generic in their health policies , said about his hope that " the use of generics is protected." " Over the coming years , there are still legal initiatives and agreements that seriously endanger the production of generics ," said in a statement José Antonio Bastos , president of the NGO. The research and development of new drugs should be no " led only by the profit motive of the pharmaceutical industry, but there are other elements and other components. Industry should be much more part of the solution of the problem . Currently Doctors Without Borders in individual cases is involved in researching new products for diseases that affect patients with few resources contributions, contributions from the pharmaceutical industry. "
0 件のコメント:
コメントを投稿